Company intelligence / Profile preview

Panetta Partners Limited

Road Town, British Virgin Islands

Ownership: Private
Development stage: Other

Overview

Panetta Partners Limited acts as an investment and intellectual property holding entity with a track record of originating and licensing drug development assets (e.g., chemerin-based peptides for treating ocular conditions, and small molecule assets for liver disease), commercializing via partnerships and assignments rather than direct clinical development[1][3].

Therapeutic areas: OphthalmologyGastroenterology
Modalities: Small moleculePeptideBiologic/Peptide-based therapies
Industry: Investors

Partnerships

OKYO Pharma (licensed Chemerin program)[1][4][8]Hepion Pharmaceuticals (acquired Rencofilstat asset)[3]On Target Therapeutics LLC (source of IP rights)[1]Tufts Medical Center (sublicense partner for IP)[1]

Beyond the preview

Go deeper on Panetta Partners Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Panetta Partners Limited.

Explore the full profile